4.7 Article

A genome-wide association study of survival in patients with sepsis

Journal

CRITICAL CARE
Volume 26, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13054-022-04208-5

Keywords

Sepsis; Genome-wide association study; Genomics; 28 days; Outcome

Funding

  1. Instituto de Salud Carlos III [CB06/06/1088, PI16/00049, PI17/00610, FI17/00177, PI19/00141, PI20/00876]
  2. European Regional Development Funds, A way of making Europe from the European Union
  3. Instituto Tecnologico y de Energias Renovables (ITER) [OA17/008]
  4. Cabildo Insular de Tenerife [CGIEU0000219140]
  5. NIHR Leicester Biomedical Research Centre
  6. Wellcome Trust [221680/Z/20/Z]
  7. NIH NHLBI [HL137006, HL137915, HL155804, PT17/0019]
  8. European Regional Development Fund
  9. PE I + D + i 2013-2016 - Instituto de Salud Carlos III [PT17/0019]
  10. GSK/Asthma + Lung UK Chair in Respiratory Research [C17-1]
  11. Wellcome Trust [221680/Z/20/Z] Funding Source: Wellcome Trust

Ask authors/readers for more resources

Sepsis is a severe systemic inflammatory response to infections with high mortality rate. First GWAS of 28-day sepsis survival identified novel variants associated with reduced survival, including a missense variant in SAMD9. Further studies with larger sample sizes are needed to validate the findings.
Background Sepsis is a severe systemic inflammatory response to infections that is accompanied by organ dysfunction and has a high mortality rate in adult intensive care units. Most genetic studies have identified gene variants associated with development and outcomes of sepsis focusing on biological candidates. We conducted the first genome-wide association study (GWAS) of 28-day survival in adult patients with sepsis. Methods This study was conducted in two stages. The first stage was performed on 687 European sepsis patients from the GEN-SEP network and 7.5 million imputed variants. Association testing was conducted with Cox regression models, adjusting by sex, age, and the main principal components of genetic variation. A second stage focusing on the prioritized genetic variants was performed on 2,063 ICU sepsis patients (1362 European Americans and 701 African-Americans) from the MESSI study. A meta-analysis of results from the two stages was conducted and significance was established at p < 5.0 x 10(-8). Whole-blood transcriptomic, functional annotations, and sensitivity analyses were evaluated on the identified genes and variants. Findings We identified three independent low-frequency variants associated with reduced 28-day sepsis survival, including a missense variant in SAMD9 (hazard ratio [95% confidence interval] = 1.64 [1.37-6.78], p = 4.92 x 10(-8)). SAMD9 encodes a possible mediator of the inflammatory response to tissue injury. Interpretation We performed the first GWAS of 28-day sepsis survival and identified novel variants associated with reduced survival. Larger sample size studies are needed to better assess the genetic effects in sepsis survival and to validate the findings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available